Dewpoint Therapeutics and Mitsubishi Tanabe link on ALS treatment
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic research partnership focusing on the development of the …
Post
-
-
LEO Pharma’s eczema cream gains MHRA marketing authorisation
LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus …
-
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to treat limited-stage small cell …
-
CEO of UnitedHealthcare, Brian Thompson, shot dead in New York City
The CEO of US healthcare insurance firm UnitedHealthcare Group has been shot dead by a masked gunman outside of the …
-
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
Eli Lilly has scored a win in the ongoing competition with Novo Nordisk in the obesity space, as a Phase …
-
Maze Therapeutics raises $115m to advance kidney disease candidates
Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 …
-
Ipsen and Biomunex enter agreement for cancer therapy
Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals for BMX-502, a first-in-class bispecific antibody designed to engage …
-
Takeda licensed for anaemia therapy by Keros Therapeutics
Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of …
-
All-in-one milling platforms: How to reduce your machinery footprint
The pharmaceutical industry is currently experiencing a surge in novel drug candidates. These new drug approvals are leading to a …
-
Trump 2.0 could see a rise in biopharmaceutical M&A deals
Trump’s return to the White House will mean a shift in personnel at the US Federal Trade Commission (FTC), which …
-
From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics
On 26 September 2024, Cobenfy (KarXT) gained US Food and Drug Administration (FDA) approval as the first novel class of …
-
Lundbeck acquires all outstanding shares of Longboard Pharma
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease …
-
Novartis and Olema expand alliance with $250m to boost breast cancer trials
Olema Oncology has announced another clinical trial collaboration and supply agreement with Novartis for a Phase III trial in metastatic …
-
Navigating medicine pricing in Turkiye: the pharmaceutical Euro exchange rate
In recent years, Turkiye’s pharmaceutical industry has grappled with significant economic challenges, not least of which is the frequent upward …
-
J&J’s sBLAs seek FDA approval of TREMFYA for paediatric conditions
Johnson & Johnson (J&J) has sought approval for TREMFYA (guselkumab) for paediatric conditions with the submission of two supplemental biologics licence …
